Surrozen, Inc. (SRZN)
NASDAQ: SRZN · Real-Time Price · USD
29.32
-0.68 (-2.27%)
At close: Oct 2, 2026, 4:00 PM EDT
29.89
+0.57 (1.94%)
After-hours: Oct 2, 2026, 7:48 PM EDT
Surrozen Employees
Surrozen had 44 employees as of December 31, 2025. The number of employees increased by 3 or 7.32% compared to the previous year.
Employees
44
Change (1Y)
3
Growth (1Y)
7.32%
Revenue / Employee
$261,614
Profits / Employee
-$7,376,455
Market Cap
344.61M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 44 | 3 | 7.32% | 44 | 0 |
| Dec 31, 2024 | 41 | -1 | -2.38% | 40 | 1 |
| Dec 31, 2023 | 42 | -32 | -43.24% | 42 | 0 |
| Dec 31, 2022 | 74 | -9 | -10.84% | 74 | 0 |
| Dec 31, 2021 | 83 | - | - | 83 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Enanta Pharmaceuticals | 120 |
| Ocugen | 116 |
| Arcturus Therapeutics Holdings | 111 |
| C4 Therapeutics | 104 |
| Orchestra BioMed Holdings | 86 |
| Zura Bio | 40 |
| Fennec Pharmaceuticals | 35 |
| Inhibikase Therapeutics | 35 |
SRZN News
- 21 hours ago - Surrozen announces FDA clearance of IND application for SZN-8141 - TheFly
- 21 hours ago - Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema - GlobeNewsWire
- 7 days ago - Surrozen price target raised to $54 from $44 at H.C. Wainwright - TheFly
- 16 days ago - Surrozen Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 22 days ago - Surrozen Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 24 days ago - Surrozen submits investigational new drug application for SZN-8141 - TheFly
- 24 days ago - Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema - GlobeNewsWire
- 4 weeks ago - Surrozen Slides: Corporate presentation - Filings